The Safety and the Efficacy of First-line Antiretroviral Treatment Regimens in Children: A Single Center Experience in Turkey

Kaba O., HANÇERLİ TÖRÜN S., Kara M., Koksal M. O., Agacfidan A., Somer A.

JOURNAL OF PEDIATRIC INFECTION, no.4, 2018 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2018
  • Doi Number: 10.5578/ced.67663
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Keywords: Toxicity, pediatric, HIV, antiretroviral treatment, resistance
  • Istanbul University Affiliated: Yes


Objective: Active antiretroviral therapy refers to the use of a combination of drugs for treating human immune deficiency virus infection with the aim of preventing long-term toxicity. Material and Methods: This study included 27 HIV-infected patients less than 18 years of age, between the years of 2001-2016. Primary outcomes were serious adverse events and virologic response to ART. Results: The mean age of the patients at the time of diagnosis was 69.2 (1-204) months. Twenty-two patients had LPV/r-based regimen as first-line ART, initially. The mean follow-up period was 67.1 (6-192) months. First line therapy was changed in 6 patients. Resistance against antiretroviral drugs was found in four patients. Conclusion: Despite small number of patients, a protease inhibitor-based regime seems to be a good option for children in immune recovery.